Maximus (MMS): The $100 Price Target and +55% Potential Upside

Key Takeaways

• The central target of $100 is the arithmetic mean of three current, attributable analyst price targets — BTIG at $100, Raymond James at $95, and Stifel at $102 — rounded to a clean level.
• With shares of MMS near $64.71, reaching $100 would require a gain of roughly 55%, a very large move.
• The verified target range is narrow, spanning about $95 to $102, although thin sell-side coverage means some aggregators show a wider band that includes older estimates.
• Supporting factors include a low valuation (a trailing P/E near 9.6), strong free cash flow, aggressive buybacks, a rising dividend, and a steady flow of government contract wins.
• Key risks are federal spending and budget-policy pressure, a divestiture that trimmed revenue guidance, and the fact that the stock has already retreated sharply from its $100 52-week high.
• For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.

Understanding the Analyst Targets for MMS

Maximus, Inc. (MMS) provides business process services that help governments administer health and human services programs. Sell-side coverage remains limited, with just a few active analysts. The three current, attributable targets are BTIG’s reiterated Buy rating and $100 target from July 2026, Raymond James analyst Brian Gesuale’s Outperform rating with a $95 target (raised from $90 in January 2026), and Stifel’s $102 target. These average roughly $99 and round to the central $100 level.

All three ratings are positive, yet the small sample size limits how much weight to place on the agreement. Some data aggregators include older or less clearly attributed estimates, which can widen the reported range to something like $75 to $110. I view the $100 figure as a straightforward average of the named, current targets rather than an official consensus number.

Where MMS Stands Today and the Path to $100

Shares of MMS closed near $64.71 in mid-November 2026, within a 52-week range of roughly $51 to $100. Reaching the central target would imply about 55% upside — a substantial move. The stock already traded near that level in the past year, touching a 52-week high around $100 before falling roughly 35%. The journey back therefore feels more like reclaiming prior ground than entering new territory.

Fundamentals look reasonable on a valuation basis. Trailing twelve-month revenue stands at about $5.25 billion, net income near $371 million, and diluted EPS around $6.76. The stock trades at a trailing P/E near 9.6 and a forward P/E near 7.8, both well below the broader market. Management narrowed fiscal 2026 revenue guidance to roughly $5.2 billion to $5.35 billion after divesting a U.S. services business, which has kept top-line expectations modest even as profitability improves. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Factors That Could Support a Move Toward the Target

• Valuation. A single-digit forward P/E leaves room for multiple expansion if earnings visibility improves.
• Capital returns. Maximus completed a large buyback program that repurchased roughly 15% of shares outstanding and raised its quarterly dividend 10% to $0.33 per share in January 2026.
• Contract momentum. Recent awards include a U.S. Air Force cyber command contract, a Massachusetts Health Connector enrollment agreement, and a Pennsylvania enrollment-assistance renewal, supporting a durable revenue base.
• Margin execution. Raymond James cited margin growth when raising its target, and EPS has grown faster than revenue in recent quarters.

Risks That Could Keep the Target Out of Reach

• Federal budget and policy pressure. Government-services revenue is sensitive to spending priorities and efficiency initiatives, which can compress or delay contract awards.
• Revenue headwinds. The divested U.S. services business trimmed guidance, and revenue is expected to decline modestly year over year in fiscal 2026.
• Technical overhang. The stock’s failure to hold near $100 and its subsequent slide suggest sellers have been active at elevated levels.
• Thin coverage and liquidity risk. With few analysts and a small float, sentiment can shift quickly without a broad institutional consensus to anchor the stock.

Technical Levels and Market Structure

The $100 level remains the key reference point: it is both the psychological round number and the stock’s 52-week high, serving as durable resistance. On the downside, the $51-to-$55 zone marks the 52-week low and a meaningful support area. The stock’s roughly 35% decline from its high, combined with a beta below 1, points to lower volatility than the broader market, yet the distance back to $100 suggests any recovery would require sustained, multi-quarter confirmation rather than a single catalyst.

Time Horizon and What to Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though thin coverage here means individual timelines may vary. The most important near-term events are the fiscal fourth-quarter earnings report (scheduled around late November 2026), management’s fiscal 2027 guidance, and any analyst target revisions that follow. Investors should also watch federal budget developments, new contract announcements, and continued progress on margins and buybacks.

Using Tickeron’s AI Daily Buy/Sell Signals for a More Dynamic View

For traders who want a more dynamic view than a static 12-month price target, Tickeron’s AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For those following MMS, it offers a complementary, data-driven way to track momentum alongside fundamental research. I find it helpful for staying on top of shorter-term movements while keeping the longer-term fundamentals in view.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Industry description

Market Cap

High and low price notable news

Volume